Dr. Lal PathLabs Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Dr. Lal PathLabs is de winst gegroeid met een gemiddeld jaarlijks percentage van 8.1%, terwijl de Healthcare industrie de winst jaarlijks groeide met 23.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 11.9% per jaar. Het rendement op eigen vermogen van Dr. Lal PathLabs is 20%, en het heeft een nettomarge van 17.1%.
Belangrijke informatie
8.1%
Groei van de winst
7.9%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 29.4% |
| Inkomstengroei | 11.9% |
| Rendement op eigen vermogen | 20.0% |
| Nettomarge | 17.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11Opbrengsten en kosten
Hoe Dr. Lal PathLabs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 23,464 | 4,014 | 4,312 | 0 |
| 30 Jun 24 | 22,875 | 3,815 | 4,227 | 0 |
| 31 Mar 24 | 22,266 | 3,577 | 4,135 | 0 |
| 31 Dec 23 | 21,722 | 3,298 | 3,856 | 0 |
| 30 Sep 23 | 21,227 | 3,013 | 3,772 | 0 |
| 30 Jun 23 | 20,552 | 2,638 | 2,869 | 0 |
| 31 Mar 23 | 20,169 | 2,388 | 3,577 | 0 |
| 31 Dec 22 | 20,114 | 2,435 | 3,349 | 0 |
| 30 Sep 22 | 20,189 | 2,480 | 3,299 | 0 |
| 30 Jun 22 | 19,835 | 2,713 | 3,255 | 0 |
| 31 Mar 22 | 20,874 | 3,448 | 3,480 | 0 |
| 31 Dec 21 | 20,329 | 3,669 | 3,303 | 0 |
| 30 Sep 21 | 19,884 | 4,041 | 3,264 | 0 |
| 30 Jun 21 | 19,219 | 3,944 | 3,126 | 0 |
| 31 Mar 21 | 15,813 | 2,916 | 2,501 | 0 |
| 31 Dec 20 | 14,520 | 2,407 | 2,343 | 0 |
| 30 Sep 20 | 13,275 | 2,003 | 2,160 | 0 |
| 30 Jun 20 | 12,612 | 1,955 | 2,079 | 0 |
| 31 Mar 20 | 13,304 | 2,259 | 2,222 | 0 |
| 31 Dec 19 | 13,298 | 2,405 | 2,540 | 0 |
| 30 Sep 19 | 12,944 | 2,322 | 2,493 | 0 |
| 30 Jun 19 | 12,463 | 2,086 | 2,412 | 0 |
| 31 Mar 19 | 12,034 | 1,992 | 2,341 | 0 |
| 31 Dec 18 | 11,691 | 1,923 | 2,294 | 0 |
| 30 Sep 18 | 11,393 | 1,825 | 2,238 | 0 |
| 30 Jun 18 | 10,999 | 1,761 | 2,173 | 0 |
| 31 Mar 18 | 10,569 | 1,707 | 2,102 | 0 |
| 31 Dec 17 | 10,100 | 1,617 | 898 | 0 |
| 30 Sep 17 | 9,548 | 1,565 | 808 | 0 |
| 30 Jun 17 | 9,389 | 1,586 | 752 | 0 |
| 31 Mar 17 | 9,124 | 1,546 | 1,694 | 0 |
| 31 Dec 16 | 8,902 | 1,576 | 700 | 0 |
| 30 Sep 16 | 8,713 | 1,876 | 676 | 0 |
| 30 Jun 16 | 8,249 | 1,413 | 625 | 0 |
| 31 Mar 16 | 7,913 | 1,322 | 580 | 0 |
| 31 Dec 15 | 7,654 | 1,201 | 2,152 | 11 |
| 31 Mar 15 | 6,596 | 908 | 497 | 0 |
| 31 Mar 14 | 5,579 | 763 | 1,755 | 10 |
Kwaliteitswinsten: LALPATHLAB heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (17.1%) LALPATHLAB } zijn hoger dan vorig jaar (14.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van LALPATHLAB is de afgelopen 5 jaar met 8.1% per jaar gegroeid.
Versnelling van de groei: De winstgroei van LALPATHLAB over het afgelopen jaar ( 33.2% ) overtreft het 5-jarig gemiddelde ( 8.1% per jaar).
Winst versus industrie: De winstgroei LALPATHLAB over het afgelopen jaar ( 33.2% ) overtrof de Healthcare -sector 33.2%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 20% ) van LALPATHLAB wordt als laag beschouwd.